Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery and therapeutic delivery of microRNAs targeting deregulated glioblastoma pathways inhibits tumor growth in mice.

The Journal of clinical investigation·2026
Same author

Microenvironment T-Type calcium channels regulate neuronal and glial processes in tumor cells to promote glioblastoma growth.

Neuro-oncology·2026
Same author

Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801).

AJNR. American journal of neuroradiology·2026
Same author

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Erratum: Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Key Considerations in Telestroke Program Management.

Continuum (Minneapolis, Minn.)·2026
Same journal

Neurology's Action Potential: Delivering on the Promise of Brain Health.

Continuum (Minneapolis, Minn.)·2026
Same journal

Erratum.

Continuum (Minneapolis, Minn.)·2026
Same journal

Management of Large Artery Atherosclerosis.

Continuum (Minneapolis, Minn.)·2026
Same journal

Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)·2026
Same journal

Stroke in Children and Younger Adults.

Continuum (Minneapolis, Minn.)·2026
See all related articles

Related Experiment Video

Updated: Feb 17, 2026

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
05:45

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Published on: January 19, 2024

2.9K

Low-grade Gliomas.

David Schiff

    Continuum (Minneapolis, Minn.)
    |December 5, 2017
    PubMed
    Summary
    This summary is machine-generated.

    Optimal low-grade glioma treatment remains complex. While radiation plus chemotherapy (PCV) offers the best survival, research continues on less toxic options like temozolomide to balance efficacy and long-term cognitive health.

    More Related Videos

    A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
    06:27

    A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

    Published on: May 9, 2025

    1.2K
    Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
    10:58

    Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

    Published on: February 22, 2015

    13.5K

    Related Experiment Videos

    Last Updated: Feb 17, 2026

    Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
    05:45

    Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

    Published on: January 19, 2024

    2.9K
    A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
    06:27

    A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas

    Published on: May 9, 2025

    1.2K
    Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
    10:58

    Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

    Published on: February 22, 2015

    13.5K

    Area of Science:

    • Neuro-oncology
    • Molecular Diagnostics
    • Clinical Trials

    Background:

    • Low-grade gliomas pose management challenges due to long survival and treatment toxicity concerns.
    • Tumor rarity complicates clinical trial design for optimal care strategies.

    Purpose of the Study:

    • To review current management issues and recent advances in low-grade glioma treatment.
    • To evaluate the role of surgery, radiation, and chemotherapy in optimizing patient outcomes.
    • To address the impact of isocitrate dehydrogenase (IDH) mutations on diagnosis and prognosis.

    Main Methods:

    • Review of current literature and clinical trial data on low-grade glioma management.
    • Analysis of diagnostic advancements, including IDH mutation status.
    • Evaluation of treatment strategies: maximal safe debulking, radiation therapy, and chemotherapy (PCV, temozolomide).

    Main Results:

    • IDH mutations improve diagnosis and risk stratification for low-grade gliomas.
    • Maximal safe tumor debulking is increasingly supported as a first-line approach.
    • Combined radiation and PCV chemotherapy demonstrated a significant survival advantage over radiation alone.
    • Chemotherapy showed comparable effectiveness to radiation for a specific molecular subtype, but overall survival data favor combination therapy.

    Conclusions:

    • The combination of radiation and PCV chemotherapy provides the most robust survival benefit for low-grade gliomas.
    • Further research is needed to assess temozolomide's efficacy compared to PCV with radiation.
    • Investigating initial chemotherapy to defer radiation-induced cognitive toxicity while maintaining survival is a key future direction.